Governance Board
Glenn Saldanha
Chairman and Managing Director, Glenmark Pharmaceuticals Limited
Glenn Saldanha is the Chairman and Managing Director of Glenmark Pharmaceuticals Limited. He joined in 1998 as Director and took over as Managing Director and CEO in 2001. As Chairman and Managing Director of Glenmark, Glenn oversees all operations of the organization.
During his tenure, he transformed Glenmark into a truly global organization with revenues of more than $1.5 billion and a commercial presence in more than eighty countries. Under his leadership, Glenmark has evolved from a generics business into a research-driven and innovation-led organization.
He holds a bachelor’s degree in pharmacy from Mumbai University in India and has a master’s degree in business administration from the Leonard Stern School of Business at New York University. Prior to Glenmark, he worked with Eli Lilly, USA and PricewaterhouseCoopers, USA.
Glenn Saldanha
Chairman and Managing Director, Glenmark Pharmaceuticals Limited
Glenn Saldanha is the Chairman and Managing Director of Glenmark Pharmaceuticals Limited. He joined in 1998 as Director and took over as Managing Director and CEO in 2001. As Chairman and Managing Director of Glenmark, Glenn oversees all operations of the organization.
During his tenure, he transformed Glenmark into a truly global organization with revenues of more than $1.5 billion and a commercial presence in more than eighty countries. Under his leadership, Glenmark has evolved from a generics business into a research-driven and innovation-led organization.
He holds a bachelor’s degree in pharmacy from Mumbai University in India and has a master’s degree in business administration from the Leonard Stern School of Business at New York University. Prior to Glenmark, he worked with Eli Lilly, USA and PricewaterhouseCoopers, USA.
Cyril Konto, M.D.
President and Chief Executive Officer, Ichnos Glenmark Innovation
Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.
At Pfizer, he was Executive Director of Early Immuno-oncology Clinical Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.
Cyril Konto, M.D.
President and Chief Executive Officer, Ichnos Glenmark Innovation
Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.
At Pfizer, he was Executive Director of Early Immuno-oncology Clinical Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.
Dennis Purcell
Founder and Former Senior Managing Partner, Aisling Capital
Dennis Purcell is the original founder of Aisling Capital LLC and currently serves as a senior advisor. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Dennis served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist) for more than five years. While at H&Q, he was directly involved with more than two hundred completed transactions and supervised more than $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries. During his tenure, BioWorld Today and other industry publications cited H&Q as the leading underwriter of life sciences securities.
Prior to joining H&Q, Dennis was a Managing Director in the Healthcare Group at PaineWebber, Inc. He is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering & Biotechnology News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen, and cited as one of the top 100 contributors to the biotechnology industry. Dennis received his master’s degree in business administration from Harvard Business School and his bachelor’s degree in accounting from the University of Delaware.
Dennis Purcell
Founder and Former Senior Managing Partner, Aisling Capital
Dennis Purcell is the original founder of Aisling Capital LLC and currently serves as a senior advisor. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Dennis served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist) for more than five years. While at H&Q, he was directly involved with more than two hundred completed transactions and supervised more than $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries. During his tenure, BioWorld Today and other industry publications cited H&Q as the leading underwriter of life sciences securities.
Prior to joining H&Q, Dennis was a Managing Director in the Healthcare Group at PaineWebber, Inc. He is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering & Biotechnology News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen, and cited as one of the top 100 contributors to the biotechnology industry. Dennis received his master’s degree in business administration from Harvard Business School and his bachelor’s degree in accounting from the University of Delaware.
Lawrence Olanoff, M.D., Ph.D.
Director, Ichnos Sciences, Adjunct Assistant Professor and Special Advisor to the President for Corporate Relations at the Medical University of South Carolina, USA
Dr. Olanoff previously served as President and Chief Operating Officer for Forest Laboratories, Inc., and Chief Executive Officer of Celsion Corporation. During his career, Dr. Olanoff made substantial contributions leading to thirty new drug approvals across several therapeutic areas. He received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University and has authored forty scientific publications on topics including drug delivery, pharmacokinetics and drug metabolism.
Lawrence Olanoff, M.D., Ph.D.
Former President and Chief Operating Officer, Forest Laboratories
Lawrence Olanoff is currently an adjunct assistant professor and special advisor to the President for Corporate Relations at the Medical University of South Carolina. Previously, he served as President and Chief Operating Officer for Forest Laboratories, Inc. from 2006 through 2010. From 2005 to 2006, Lawrence was Chief Executive Officer of Celsion Corporation. He also served as Executive Vice President of Research and Development and Chief Scientific Officer of Forest from 1995 to 2005. Prior to joining Forest, Lawrence served in senior clinical research roles at Sandoz Pharmaceutical Corporation and at The Upjohn Company.
During his pharmaceutical development career, Lawrence made substantial contributions leading to thirty new drug approvals, either as new chemical entities or as supplemental indications, over a range of therapeutic areas. He serves as a member of the Board of Ironwood Pharmaceuticals as well as several nonprofit organizations.
Lawrence also held past directorships on the Boards of Forest Laboratories, Axovant Sciences Ltd., and the Celsion Corporation. He received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University, was an internal medicine resident and clinical pharmacology fellow at the Medical University of South Carolina, and is the author of some forty scientific publications on topics including controlled drug delivery, pharmacokinetics, drug metabolism, and clinical toxicology.
Lawrence Olanoff, M.D., Ph.D.
Former President and Chief Operating Officer, Forest Laboratories
Lawrence Olanoff is currently an adjunct assistant professor and special advisor to the President for Corporate Relations at the Medical University of South Carolina. Previously, he served as President and Chief Operating Officer for Forest Laboratories, Inc. from 2006 through 2010. From 2005 to 2006, Lawrence was Chief Executive Officer of Celsion Corporation. He also served as Executive Vice President of Research and Development and Chief Scientific Officer of Forest from 1995 to 2005. Prior to joining Forest, Lawrence served in senior clinical research roles at Sandoz Pharmaceutical Corporation and at The Upjohn Company.
During his pharmaceutical development career, Lawrence made substantial contributions leading to thirty new drug approvals, either as new chemical entities or as supplemental indications, over a range of therapeutic areas. He serves as a member of the Board of Ironwood Pharmaceuticals as well as several nonprofit organizations.
Lawrence also held past directorships on the Boards of Forest Laboratories, Axovant Sciences Ltd., and the Celsion Corporation. He received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University, was an internal medicine resident and clinical pharmacology fellow at the Medical University of South Carolina, and is the author of some forty scientific publications on topics including controlled drug delivery, pharmacokinetics, drug metabolism, and clinical toxicology.
V. S. Mani
Chief Financial Officer, Glenmark Pharmaceuticals Limited
V. S. Mani is the Executive Director & Global Chief Financial Officer of Glenmark Pharmaceuticals Limited. He is responsible for the company’s worldwide finance operations and secretarial function, including global accounting and financial reporting as well as tax and treasury functions.
Mani is a qualified Chartered Accountant from India and has nearly thirty years of rich industry experience across treasury, taxation (direct, indirect, and international), accounting, financial planning and analysis, secretarial, legal, audits (internal and statutory), risk management, and investor relations.
Prior to joining Glenmark in 2017, he was the President-Finance at the Bhartiya Group. Mani has also held the position of the Chief Financial Officer at Cipla Ltd. and played a key role in the acquisition of various companies in emerging and mature markets for the organization.
V. S. Mani
Chief Financial Officer, Glenmark Pharmaceuticals Limited
V. S. Mani is the Executive Director & Global Chief Financial Officer of Glenmark Pharmaceuticals Limited. He is responsible for the company’s worldwide finance operations and secretarial function, including global accounting and financial reporting as well as tax and treasury functions.
Mani is a qualified Chartered Accountant from India and has nearly thirty years of rich industry experience across treasury, taxation (direct, indirect, and international), accounting, financial planning and analysis, secretarial, legal, audits (internal and statutory), risk management, and investor relations.
Prior to joining Glenmark in 2017, he was the President-Finance at the Bhartiya Group. Mani has also held the position of the Chief Financial Officer at Cipla Ltd. and played a key role in the acquisition of various companies in emerging and mature markets for the organization.
Alind Sharma
Chief Human Resources Officer, Glenmark Pharmaceuticals Limited
Alind Sharma is President and Chief Human Resources Officer of Glenmark Pharmaceuticals Limited. He is responsible for driving organizational advancement through effective human capital strategy. His areas of focus comprise enriching and developing the organization’s diverse talent, appropriate and timely rewards through robust performance management, leadership development and talent engagement.
Previously, Alind served as Vice President of Human Capital at Optum, a part of the United Health Group. He is a graduate of the Indian Institute of Management in Ahmedabad, India.
Alind Sharma
Chief Human Resources Officer, Glenmark Pharmaceuticals Limited
Alind Sharma is President and Chief Human Resources Officer of Glenmark Pharmaceuticals Limited. He is responsible for driving organizational advancement through effective human capital strategy. His areas of focus comprise enriching and developing the organization’s diverse talent, appropriate and timely rewards through robust performance management, leadership development and talent engagement.
Previously, Alind served as Vice President of Human Capital at Optum, a part of the United Health Group. He is a graduate of the Indian Institute of Management in Ahmedabad, India.
Glenn Saldanha
Glenn Saldanha is the Chairman and Managing Director of Glenmark Pharmaceuticals Limited. He joined in 1998 as Director and took over as Managing Director and CEO in 2001. As Chairman and Managing Director of Glenmark, Glenn oversees all operations of the organization.
During his tenure, he transformed Glenmark into a truly global organization with revenues of more than $1.5 billion and a commercial presence in more than eighty countries. Under his leadership, Glenmark has evolved from a generics business into a research-driven and innovation-led organization.
He holds a bachelor’s degree in pharmacy from Mumbai University in India and has a master’s degree in business administration from the Leonard Stern School of Business at New York University. Prior to Glenmark, he worked with Eli Lilly, USA and PricewaterhouseCoopers, USA.
Cyril Konto, M.D.
Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies.
At Pfizer, he was Executive Director of Early Immuno-oncology Clinical Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.
Dennis Purcell
Dennis Purcell is the original founder of Aisling Capital LLC and currently serves as a senior advisor. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Dennis served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist) for more than five years. While at H&Q, he was directly involved with more than two hundred completed transactions and supervised more than $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries. During his tenure, BioWorld Today and other industry publications cited H&Q as the leading underwriter of life sciences securities.
Prior to joining H&Q, Dennis was a Managing Director in the Healthcare Group at PaineWebber, Inc. He is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering & Biotechnology News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen, and cited as one of the top 100 contributors to the biotechnology industry. Dennis received his master’s degree in business administration from Harvard Business School and his bachelor’s degree in accounting from the University of Delaware.
Lawrence Olanoff, M.D., Ph.D.
Former President and Chief Operating Officer, Forest Laboratories
Lawrence Olanoff is currently an adjunct assistant professor and special advisor to the President for Corporate Relations at the Medical University of South Carolina. Previously, he served as President and Chief Operating Officer for Forest Laboratories, Inc. from 2006 through 2010. From 2005 to 2006, Lawrence was Chief Executive Officer of Celsion Corporation. He also served as Executive Vice President of Research and Development and Chief Scientific Officer of Forest from 1995 to 2005. Prior to joining Forest, Lawrence served in senior clinical research roles at Sandoz Pharmaceutical Corporation and at The Upjohn Company.
During his pharmaceutical development career, Lawrence made substantial contributions leading to thirty new drug approvals, either as new chemical entities or as supplemental indications, over a range of therapeutic areas. He serves as a member of the Board of Ironwood Pharmaceuticals as well as several nonprofit organizations.
Lawrence also held past directorships on the Boards of Forest Laboratories, Axovant Sciences Ltd., and the Celsion Corporation. He received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University, was an internal medicine resident and clinical pharmacology fellow at the Medical University of South Carolina, and is the author of some forty scientific publications on topics including controlled drug delivery, pharmacokinetics, drug metabolism, and clinical toxicology.
V. S. Mani
V. S. Mani is the Executive Director & Global Chief Financial Officer of Glenmark Pharmaceuticals Limited. He is responsible for the company’s worldwide finance operations and secretarial function, including global accounting and financial reporting as well as tax and treasury functions.
Mani is a qualified Chartered Accountant from India and has nearly thirty years of rich industry experience across treasury, taxation (direct, indirect, and international), accounting, financial planning and analysis, secretarial, legal, audits (internal and statutory), risk management, and investor relations.
Prior to joining Glenmark in 2017, he was the President-Finance at the Bhartiya Group. Mani has also held the position of the Chief Financial Officer at Cipla Ltd. and played a key role in the acquisition of various companies in emerging and mature markets for the organization.
Alind Sharma
Alind Sharma is President and Chief Human Resources Officer of Glenmark Pharmaceuticals Limited. He is responsible for driving organizational advancement through effective human capital strategy. His areas of focus comprise enriching and developing the organization’s diverse talent, appropriate and timely rewards through robust performance management, leadership development and talent engagement.
Previously, Alind served as Vice President of Human Capital at Optum, a part of the United Health Group. He is a graduate of the Indian Institute of Management in Ahmedabad, India.